The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.

Explore QuantumScape's Q1 2025 earnings call insights, featuring progress on solid-state battery tech, Cobra process milestones, and partnerships ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...